

# Announcement

---

## SYNOPSIS

### *IN VIVO* SCREENING OF MATERIALS FROM EUROPEAN SOURCES

The National Cancer Institute (NCI), Division of Cancer Treatment (DCT), Developmental Therapeutics Program (DTP), Drug Evaluation Branch (DEB) is seeking organizations in Western Europe for primary and detailed *in vivo* testing, in rodent hosts, for anticancer efficacy. Animals, tumors and testing protocols will be supplied by the NCI. Materials to be tested will be supplied by the NCI primarily through the NCI Liaison Office based in Europe. The NCI is seeking organizations possessing facilities for housing sufficient numbers of conventional experimental rodents and possessing the capability to maintain and transplant tumor lines, to prepare materials for testing, to conduct a minimum of 11,000 test equivalents per year and to report all test data for computer processing on forms and format furnished by the NCI. A test equivalent is based on the work effort required to carry out an IP L1210 assay, with IP treatment for 9 consecutive days using 6 mice per test group plus appropriate controls. Organizations must have the capability to conduct testing in a number of *in vivo* tumor assays, primarily the P388 tumor test system and other systems such as L1210, B16 melanoma, M5076, etc. Testing against human tumor xenograft is not required.

Volunteers must possess the capability and resources for *in vivo* screening at a minimum level of 11,000 L1210 test equivalents per year. The Principal Investigator must have experience in the *in vivo* testing of drugs in rodents.

It is anticipated that one award will be made as a result of this RFP. It is also anticipated that the award will be for a 5-year incrementally funded period of performance. Some form of cost-sharing is encouraged.

This synopsis is not a request for proposal. RFP No. NCI-CM-47645-24 for the above-described work will be available to interested contractors on or after 19 December 1983. Copies of the RFP may be obtained by sending a written request to:

NCI, Treatment Contracts Section,  
9000 Rockville Pike,  
Blair Building, Room 228,  
Bethesda, MD 20205, U.S.A.  
Attention: Mrs. Marlene Haywood, Contract Specialist,  
Treatment Contract Section, Research Contracts Branch.